MEDIA LIBRARY

REDUCTION OF PRODUCT-RELATED IMPURITIES DURING PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUSES

Article by CEVEC authors Dr. Michelle Hussong, Dr. Tobias Bonifert, Prof. Dr. Nico Scheer

BioPharm International, June 9, 2022

HOW TO ADDRESS CHALLENGES IN PRODUCING AAV VECTORS

Interview with Ines do Carmo Gil-Goncalves, PhD, head of vector production for Cevec Pharmaceuticals at the ASGCT Meeting 2022.

ASGCT ANNUAL MEETING 2002 – May 23, 2022

ADVANCED TECHNOLOGIES FOR SCALABLE AAV VECTOR PRODUCTION

Free Online Seminar by Dr. Nicole Faust, CEO. Learn about the latest developments in using stable producer cell lines for AAV manufacturing and how the ELEVECTA® system enables a fully scalable and robust vector production process without plasmid transfection or helper viruses.

Cell & Gene Therapy Manufacturing & Commercialization Digital Week – May 3, 2022

CEVEC PHARMACEUTICALS CEO STRESSES CHALLENGES IN PRODUCING AAV VECTORS

Interview with Dr. Nicole Faust, CEO of CEVEC Pharmaceuticals at the Cell & Gene Meeting on the Med in Barcelona, Spain.

The Science Advisory Board – April 26, 2022

GENE THERAPY ON THE VERGE OF TAKING ITS NEXT EVOLUTIONARY STEP

Interview by Dr. Nicole Faust, CEO of CEVEC Pharmaceuticals

Pharm Exec.com, Brand Insights Contributor – April 22, 2022 

MANUFACTURING OF RCA-FREE ADENOVIRAL VECTORS

Free Online Seminar by Dr. Nico Scheer, Senior Consultant, Business Development, CEVEC Pharmaceuticals / Professor “Molecular Biology“, FH Aachen University of Applied Sciences

Cell & Gene Therapy Insights – February 22, 2022

Complimentary live 30 poster

MANUFACTURING OF RCA-FREE ADENOVIRAL VECTOR VACCINES

Sponsored article by CEVEC authors Silke Wissing, Helmut Kewes and Nico Scheer

Genetic Engineering & Biotechnology News (GEN) – December 3, 2021

TRANSFER AND SCALE-UP FROM 10 L BIOBLU® TO ALLEGRO™ STR 50 AND STR 200 BIOREACTORS

In this article, David Mainwaring et al. discuss Pall and CEVEC’s recent collaboration to demonstrate scalability of a transient transfection-free, stable AAV producer cell line from the bench-scale 10L production bioreactors to the Pall Allegro™ STR 50L and STR 200L bioreactors.

Cell & Gene Therapy, Bio Insights – November 25, 2021

CAP®AD – A VERSATILE PLATFORM FOR RCA-FREE, INDUSTRIAL SCALE ADENOVIRAL VECTOR PRODUCTION

White Paper by CEVEC authors Silke Wissing, Helmut Kewes and Nico Scheer

Bioprocess International Magazine, Multimedia Placement, October 2021

MANUFACTURING ADENOVIRAL VECTORS AT LARGE SCALE

How to select the best process and cell line to avoid RCA formation

Sponsored article by CEVEC authors Silke Wissing, Nicole Faust and Nico Scheer, Page 35

Genetic Engineering & Biotechnology News (GEN) – 40th Anniversary Edition, October 2021

HIGH TITER rAAV PRODUCTION IN BIOREACTOR USING ELEVECTA® STABLE PRODUCER CELL LINES

Scientific Poster, J. Coronel, A. Al-Dali, A. Patil, K. Srinivasan, T. Braß, K. Hein, S. Wissing

ESGCT 2021, October 2021

DEVELOPMENT OF A HEK293-BASED FULLY STABLE,
HELPER VIRUS-FREE ELEVECTA PRODUCTION SYSTEM FOR rAAV

Scientific Poster, B Hudjetz, S Schmidt-Hertel, T Grabeck, K Srinivasan, A Al-Dali, J Coronel, N Strempel, N Faust, S Wissing

ESGCT 2021, October 2021

AAV MANUFACTURING WITH STABLE PRODUCER CELLS FOR INDUSTRIAL SCALE VECTOR PRODUCTION

Free Online Seminar, Dr. Ben Hudjetz, Senior Scientist Cell Line Development, CEVEC

Cell & Gene Therapy, Bio Insights – September 16, 2021

GENTHERAPIEN MIT AAV-VEKTOREN

CEVEC Pharmaceuticals: Hochleistungszelltechnologien für Biotherapeutika

Interview mit Dr. Nicole Faust, CEO, CEVEC

Plattform Life Science – September 2021

ELEVECTA® – THE FUTURE OF AAV GENE THERAPY VECTOR PRODUCTION

Pharmaceutical companies with gene therapies in their pipeline need to establish scalable production processes that can keep up with the increasing demand in terms of volume, quality and robustness, says CEVEC.

BPI Contributor – November 3, 2020 

HOW TO SOLVE THE PRODUCTION CHALLENGES OF AAVS FOR GENE THERAPY

CEVEC Pharmaceuticals has found a solution and developed a platform that can produce adeno-associated viral vectors (AAVs) as easily as if they were monoclonal antibodies.

Labiotech.eu – June 3, 2020

Read the interview with Nicole Faust, CEO of CEVEC

CEVEC PHARMACEUTICALS GMBH HAS LAUNCHED A NEW, SCALABLE PRODUCTION PLATFORM FOR AAV GENE THERAPY VECTORS.

At the time of Cevec Pharmaceuticals’s announcement, US researchers reported that AAV gene therapy might be the most promising way to bridge the therapeutic gap until a COVID-19 vaccine is available.

European Biotechnology – April 29, 2020

© CEVEC Pharmaceuticals GmbH 2022